Screener
Kura Oncology KURA Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other income, net | 5,490 | 7,497 |
| Loss before income taxes | (73,325) | (57,203) |
| Income tax expense | 8 | 226 |
| Net Loss | $(73,333) | $(57,429) |
| Net loss per share, basic and diluted | $(0.83) | $(0.66) |
| Weighted average number of shares used in computing net loss per share, basic and diluted | 88,610 | 87,415 |
| Comprehensive Loss | ||
| Net loss | $(73,333) | $(57,429) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's net income?
- Kura Oncology (KURA) reported net income of -$73.33M in Q1 2026.
- How has Kura Oncology's net income changed year-over-year?
- Kura Oncology's net income decreased by 27.7% year-over-year, from -$57.43M to -$73.33M.
- What is the long-term trend for Kura Oncology's net income?
- Over 4 years (2021 to 2025), Kura Oncology's net income has grown at a 20.9% compound annual growth rate (CAGR), from -$130.47M to -$278.67M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Kura Oncology's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude